PharmaJet Partner, Scancell, Announces Positive Data from the First Stage of its Phase 2 Trial of Advanced Melanoma DNA Vaccine delivered Needle-free
It’s been a good week for Scancell’s shareholders, as investors seized on early data from the biotech's phase 2 cancer vaccine trial to send its stock up 20%.
Scancell Holdings PLC have shared early results from its phase 1/2 cancer study which appear “very encouraging”, according to one of the investigators supervising the trial. The ModiFY clinical trial has seen the company’s Modi-1 vaccine given to patients with various hard-to-treat cancers.
UK-based biotech Scancell is lifting the veil off a Phase I trial for its Covid-19 vaccine, but it’ll also be making a pivot on the vaccine’s strategy.
GOLDEN, Colo.--(BUSINESS WIRE)--PharmaJet®, a biotech company that, with their innovative needle-free technology, has developed a more effective way of administering drugs and biologics to accelerate research, commercialization and public health outcomes, announced that its partner, Scancell, will include needle-free delivery of their Phase 2 clinical study for treatment of patients with advanced melanoma.
Scancell, a company which specialises in treating cancer and infectious diseases, has announced the enrolment and treatment of the first patient in its multicentre Modi-1 clinical trial (ModiFY) at Imperial College London, Hammersmith Hospital.
Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) said it had dosed its first patient with the second vaccine candidate being assessed in its early stage Covid trial in South Africa.
GOLDEN, Colo.--(BUSINESS WIRE)--PharmaJet®, the maker of innovative, needle-free injection technology, today announced that its partner, Scancell, has selected its devices to administer its two SARS-CoV-2 DNA vaccine candidates, SCOV1 and SCOV2. The vaccines will be exclusively administered using the PharmaJet Tropis® and PharmaJet Stratis® Needle-free Injection Systems.
Update on SCIB2 clinical development partnership
(Alliance News) - Scancell Holdings PLC on Thursday said it has secured funding from Innovate UK to start a phase 1 clinical trial of its Covid-19 vaccine in 2021.